华法林药物基因组学的研究推动其个体化医疗的进程

被引：5

作者：

曾婷

陈苏红

刘志红

王升启

机构：

[1] 军事医学科学院放射与辐射医学研究所

来源：

中国药理学与毒理学杂志 | 2009年 / 23卷 / 02期

关键词：

华法林; 药物基因组学; 治疗,个体化;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

药物基因组学可以帮助人们更好地认识药物与机体之间的相互作用。华法林是临床上广泛使用的香豆素类口服抗凝血药,其狭窄的抗凝治疗指数范围和抗凝不当所致的并发症一直困扰着临床医师,如何合理使用已经成为一个难题。近年来,随着药物基因组学的快速发展,研究发现药动学和药效学多个相关基因的多态性造成了个体差异,影响了华法林的使用剂量。本文综述了药物基因组学研究在华法林用药中的国内外最新进展,为华法林个体化医疗提供参考依据。

引用

页码：146 / 151

页数：6

共 10 条

[1] Association of warfarin dose with genes involved in its action and metabolism [J].

Wadelius, Mia ;

Chen, Leslie Y. ;

Eriksson, Niclas ;

Bumpstead, Suzannah ;

Ghori, Jilur ;

Wadelius, Claes ;

Bentley, David ;

McGinnis, Ralph ;

Deloukas, Panos .

HUMAN GENETICS, 2007, 121 (01) :23-34

[2]

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans[J] . Harumi Takahashi,Grant R. Wilkinson,Edith A. Nutescu,Takashi Morita,Marylyn D. Ritchie,Maria G. Scordo,Vittorio Pengo,Martina Barban,Roberto Padrini,Ichiro Ieiri,Kenji Otsubo,Toshitaka Kashima,Sosuke Kimura,Shinichi Kijima,Hirotoshi Echizen.Pharmacogenetics and Genomics . 2006 (2)

[3] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients [J].

Mushiroda, T ;

Ohnishi, Y ;

Saito, S ;

Takahashi, A ;

Kikuchi, Y ;

Saito, S ;

Shimomura, H ;

Wanibuchi, Y ;

Suzuki, T ;

Kamatani, N ;

Nakamura, Y .

JOURNAL OF HUMAN GENETICS, 2006, 51 (03) :249-253

[4] A C1173T dimorphism in the VKORC1 gene determines coumarin Sensitivity and bleeding risk [J].

Reitsma, PH ;

van der Heijden, JF ;

Groot, AP ;

Rosendaal, FR ;

Büller, HR .

PLOS MEDICINE, 2005, 2 (10) :996-998

[5] A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance [J].

Bodin, L ;

Horellou, MH ;

Flaujac, C ;

Loriot, MA ;

Samama, MM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) :1533-1535

[6]

Pharmacogenetics and Anticoagulant Therapy[J] . Brian F. Gage,Charles S. Eby.Journal of Thrombosis and Thrombolysis . 2003 (1)

[7]

Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population[J] . European Journal of Clinical Pharmacology . 2003 (4)

[8]

CYP2C9 allelic variants: ethnic distribution and functional significance[J] . Hong-Guang Xie,Harish C Prasad,Richard B Kim,C.Michael Stein.Advanced Drug Delivery Reviews . 2002 (10)

[9] Cytochrome P450 polymorphisms are associated with reduced warfarin dose [J].

Freeman, BD ;

Zehnbauer, BA ;

McGrath, S ;

Borecki, I ;

Buchman, TG .

SURGERY, 2000, 128 (02) :281-285

[10]

Drug-metabolismresearch challenges in the newmillenni-um:individual variability in drug therapy and drug safety. Lu AY. Drug Metabolism and Disposition . 1998

← 1 →